TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement
MALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Company's Liora Monofilament Scaffold (“Liora”) product.
Covered in this story
Call it yourself
No calls on $TELA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on TELA Bio →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.